Drug-eluting coatings. From history to practice
Olga A. Sindeeva, 1, Arkady S. Abdurashitov, 1,2, Pavel I. Proshin, 2, Gleb B. Sukhorukov, 1,2; 1Skolkovo Institute of Science and Technology, Moscow, Russia; 2 Life Improvement by Future Technologies Center, Moscow, Russia
Abstract
Drug-eluting coatings are actively used in clinical practice to reduce the risk of vascular restenosis during the implantation of coronary and peripheral vascular stents during las 10-20 years. Simultaneously, the need to correct the pathological growth of connective tissue also exists for other types of stents, implantable products, and devices. The second, equally important problem is the development of peri-implant infections. Despite all efforts, peri-implant infections are a frequent complication of any surgical intervention, especially those associated with implantation. Nevertheless, unlike intravascular stents, drug-releasing coatings for other types of implantable materials are still not available in the market and remain at the stage of development and individual clinical trials. In our laboratory, we have developed coatings based on polylactic acid and its copolymers to reduce the risks of restenosis during stenting of biliary and pancreatic ducts, restenosis of the bladder neck after resection of prostate adenoma, and the development of peri-implant infections during the installation of individual bone implants in cancer patients.
Speaker
Olga Sindeeva
Skolkovo Institute of Science and Technology
Russia
Discussion
Ask question
